

**Registration of a Patent related to Noile-Immune's Developed Technology Completed in Japan
~ Further Strengthening Intellectual Property Platform in CAR-T-related Technology Area ~**

Noile-Immune Biotech Inc. (hereinafter referred to as “Noile-Immune”) hereby announces that a newly granted patent regarding its cancer immunotherapy technologies in research and development (R&D) has been published. This further strengthened Noile-Immune's intellectual property portfolio in technology areas which Noile-Immune is focusing primarily on advancing, and made it possible to enhance the technological advantage with a view toward global expansion.

The most recently registered patents are classified into the following technology categories.

- Technology category : CAR-T-related technology
- Country of registration : Japan

This patent is based on Noile-Immune's core platform, “PRIME (Proliferation-Inducing and Migration-Enhancing)” technology, and support multiple research and development themes aimed at enhancing the efficacy, safety, and productivity of CAR-T cell therapy. Specific patent information is not disclosed from the perspective of Noile-Immune's intellectual property strategy.

Noile-Immune continue to strategically leverage each country's patent system and swiftly and accurately protect research achievements as intellectual property, thereby promoting enhance of its competitiveness in the global market. Moreover, through obtaining intellectual property, Noile-Immune will further strengthen collaborative research and licensing activities with domestic and international partners, accelerating the societal implementation of next-generation cell therapies.

【Noile-Immune Biotech Inc.】

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit <https://www.noile-immune.com/en.html>.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

E-mail: pr@noile-immune.com